Please assess the completion status of the following clinical trial:

Trial Title: Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and unifocal breast carcinoma~* Largest tumor lesion ≤ 5 cm~* Palpable or nonpalpable breast lesion~  * Preoperative radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions~* Prior (preoperative) or planned (intraoperative) sentinel node biopsy required~  * At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension~* No clinical evidence of distant metastases~  * No suspicious manifestation of metastases that cannot be ruled out by x-ray, MRI, or CT scan, including the following:~    * Skeletal pain of unknown cause~   * Elevated alkaline phosphatase~   * Bone scan showing hot spots~* No palpable axillary lymph node(s)~* No Paget's disease without invasive cancer~* Hormone receptor status:~  * Estrogen receptor and progesterone receptor known~PATIENT CHARACTERISTICS:~Age~* Any age~Sex~* Female~Menopausal status~* Any status~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* See Disease Characteristics~Renal~* Not specified~Other~* Not pregnant or nursing~* No other prior or concurrent malignancy except the following:~  * Adequately treated basal cell or squamous cell skin cancer~ * Adequately treated carcinoma in situ of the cervix~ * Adequately treated in situ melanoma~ * Contralateral or ipsilateral carcinoma in situ of the breast~* No psychiatric, addictive, or other disorder that may compromise ability to give informed consent~* Geographically accessible for follow-up~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* See Disease Characteristics~Other~* No prior systemic therapy for breast cancer~* More than 1 year since prior chemopreventive agent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Axillary Dissection (Type: ACTIVE_COMPARATOR): Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.
- No Axillary Dissection (Type: EXPERIMENTAL): Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).